Eurofins to buy Denmark's VBM Laboratories
24 March 2017
Eurofins Scientific, a provider of DNA sequencing service, today struck a deal to buy VBM Laboratories, one of the leading laboratories for testing for the environment and construction materials sectors in Denmark, for an undisclosed sum.
Founded in 1985, VBM has developed into one of the top three environment testing laboratories in the country for testing of contaminated soil and building materials particularly within the construction sector.
The company employs 80 people across its 3 sites, and generated revenues in excess of DKK 45 million in 2016.
VBM's primary competencies and customer segments in environment testing will complement Eurofins' capabilities in the local market.
The acquisition of VBM will further strengthen, as well as expand the Eurofins leadership in the Danish environment testing market.
As part of the transaction, current VBM leader Jesper Gamst will remain as managing director of VBM Laboratories.
Klaus Melsing Bjørnholdt and Jesper Gamst, VBM shareholders, said, ''We are proud to have developed VBM Laboratories to be one of the market leaders in Denmark and we are convinced that the agreement with Eurofins will safeguard further positive development for VBM and its team.''
Dr. Gilles Martin, Eurofins CEO, said, ''The acquisition of VBM demonstrates our commitment to continually reinforce our leadership in markets where we are active. The complementary businesses of VBM and Eurofins also illustrate the Group's strategy of expanding our leading operational footprint.
Eurofins is the world leader in food, environment and pharmaceutical products testing and is also one of the global independent market leaders in certain testing and laboratory services for agroscience, genomics, discovery pharmacology and for supporting clinical studies.
With over 27,000 employees in 310 laboratories across 39 countries and annual revenues of €2.54 billion, Luxembourg-based Eurofins has a portfolio of over 130,000 analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products, as well as for innovative clinical diagnostic.